Post-Exposure Prophylaxis with SA58 (anti-COVID-19 monoclonal antibody) Nasal Spray for the prevention of symptomatic Coronavirus Disease 2019 in healthy adult workers: A randomized, single-blind, placebo-controlled clinical study

Rui Song, Gang Zeng, Jianxing Yu, Xing Meng, Xiaoyou Chen, Jing Li, Xiaoliang Xie, Xiaojuan Lian, Zhiyun Zhang, Yunlong Cao, Weidong Yin, Ronghua Jin
doi: https://doi.org/10.1101/2022.12.28.22283666

Article usage

Article usage: January 2023 to June 2025

AbstractFullPdf
Jan 2023104114196
Feb 2023175741
Mar 2023267529
Apr 2023189218
May 2023158673
Jun 202376819
Jul 20237866
Aug 2023581110
Sep 202355512
Oct 20233663
Nov 202396196
Dec 20233606
Jan 20245174
Feb 202458014
Mar 202442418
Apr 20242848
May 20242435
Jun 20244963
Jul 202441316
Aug 202423915
Sep 202437917
Oct 20241746
Nov 20242325
Dec 20244043
Jan 202517417
Feb 2025292411
Mar 2025434412
Apr 202530323
May 2025481120
Jun 2025443
Back to top
Posted January 04, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Post-Exposure Prophylaxis with SA58 (anti-COVID-19 monoclonal antibody) Nasal Spray for the prevention of symptomatic Coronavirus Disease 2019 in healthy adult workers: A randomized, single-blind, placebo-controlled clinical study
Rui Song, Gang Zeng, Jianxing Yu, Xing Meng, Xiaoyou Chen, Jing Li, Xiaoliang Xie, Xiaojuan Lian, Zhiyun Zhang, Yunlong Cao, Weidong Yin, Ronghua Jin
medRxiv 2022.12.28.22283666; doi: https://doi.org/10.1101/2022.12.28.22283666
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area